Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4671010 | 1.00 | SLC22A6 (0.60) | SLC22A6LMNAGABRR1MAPTSMN1; SMN2 | |
| SCHEMBL6557026 | 1.00 | SLC22A6 (0.60) | SLC22A6LMNAGABRR1MAPTSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL6555061 | 0.97 | SLC22A6 (0.57) | SLC22A6LMNAGABRR1MAPTSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL6555178 | 0.97 | SLC22A6 (0.57) | SLC22A6LMNAGABRR1MAPTSMN1; SMN2 | |
| SCHEMBL6453593 | 0.89 | SLC22A6 (0.75) | SLC22A6LMNAGABRR1MAPTSMN1; SMN2 | |
| SCHEMBL3447372 | 0.86 | — | — | |
| SCHEMBL415844 | 0.86 | — | — | |
| SCHEMBL415845 | 0.86 | — | — | |
| SCHEMBL7465733 | 0.83 | — | — | |
| SCHEMBL7465718 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080289056-A1 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STATIN INTERMEDIATES | VERENIUM CORPORATION (US) | 2008-11-20 | — | — | US | claimed |
| EP-1625223-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STATIN INTERMEDIATES | Diversa Corporation (US) | 2006-02-15 | — | — | EP | claimed |
| US-20050153407-A1 | Chemoenzymatic methods for the synthesis of statins and stain intermediates | VERENIUM CORPORATION | 2005-07-14 | — | — | US | claimed |
| WO-2004027075-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STAIN INTERMEDIATES | DIVERSA CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| EP-1184380-B1 | Ammonium 3,5,6-trihydroxyhexanoate derivatives and preparation process thereof | TAKASAGO PERFUMERY CO LTD (JP) | 2004-02-25 | — | — | EP | claimed |
| US-20020052515-A1 | Ammonium 3,5,6-trihydroxyhexanoate derivatives and preparation process thereof | TAKASAGO INTERNATIONAL CORPORATION | 2002-05-02 | — | — | US | claimed |
| US-6365755-B1 | REACTING 3,5,6-TRIHYDROXYHEXANOIC ACID WITH AN AMINE THEN PURIFYING THE RESULTING AMMONIUM COMPOUND BY CRYSTALLIZATION; CHEMICAL INTERMEDIATES FOR HMG-COA REDUCTASE INHIBITOR; STABILITY; PREFERENTIAL STEREOCONFIGURATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-04-02 | — | — | US | claimed |
| EP-1184380-A1 | Ammonium 3,5,6-trihydroxyhexanoate derivatives and preparation process thereof | Takasago International Corporation (JP) | 2002-03-06 | — | — | EP | claimed |
| EP-0583171-B1 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | TAKASAGO PERFUMERY CO LTD (JP) | 1998-11-11 | — | — | EP | claimed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | claimed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | claimed |
| US-9228214-B2 | Process for the enantioselective enzymatic reduction of hydroxy keto compounds | CAMBREX IEP GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20150152451-A1 | PROCESS FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF HYDROXY KETO COMPOUNDS | CAMBREX IEP GMBH (DE) | 2015-06-04 | — | — | US | disclosed |
| US-8980592-B2 | Process for the enantioselective enzymatic reduction of hydroxy keto compounds | CAMBREX IEP GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8148324-B2 | Aldolases, nucleic acids encoding them; improving thermal stability of enzyme; biosynthesis of atorvastatin, rosuvastatin, fluvastatin starting from e.g. acetaldehyde and chloroacetaldehyde, using enzyme 2-deoxyribose-5-phosphate aldolase (DERA) to form pyran intermediate | VERENIUM CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | disclosed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | disclosed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | disclosed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | disclosed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052515-A1 | Ammonium 3,5,6-trihydroxyhexanoate derivatives and preparation process thereof | ABHD5, ALKBH3, APEH | SLC22A6 2714/4885LMNA 4459/4885GABRR1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.